Background Chronic viral infections caused by highly contagious human papillomaviruses (HPVs) from the alpha genus are a substantial risk factor for tumour diseases.
Introduction
Chronic viral infections are a major risk factor for neoplastic diseases and of high interest in clinical research. 1 Of the 2.2 million new cancer cases attributable to carcinogenic infections worldwide in 2012, 640 000 were caused by human papillomaviruses, thus constituting the second largest contributor to the carcinogenic infections after Helicobacter pylori (770 000 cases). 2 Human papillomaviruses belong to the ever-growing family of papillomaviridae, as defined by the International Committee for Taxonomy of Viruses (ICTV). They are non-enveloped DNA viruses with a small, annular, double-stranded genome consisting of about 6.800-8.000 bp. 3 Based on their DNA, five genera can be subdivided in more than 225 genotypes of papillomaviridae: alpha (a)-papillomavirus, beta (b)-papillomavirus, gamma (c)-papillomavirus, mu (l)-papillomavirus and nu (m)-papillomavirus. 4 Human papillomaviruses infect multi-layered epithelia like keratinocytes of the mucosa or cutaneous epithelium, and can also be subdivided into so-called 'low-risk' (lr) and 'high-risk' (hr) HPVs, based on their risk of inducing neoplastic transformation. 5, 6 Alpha-papillomaviruses mainly infect the anogenital tract and can cause various benign and malignant tumours according to their oncogenic potential. 7 The main risk factor for the development of anogenital squamous cell carcinoma (SCC) is the persistent infection with hr HPV. 8 In cervical carcinoma, hr HPV types were detected in 99.7 % of cervical cancers. 9 Furthermore, hr HPVs are associated with 43 % of vulvar cancers, with 50 % of penile carcinomas, with 70 % of vaginal carcinomas and with 88 % of anal carcinomas of both sexes. 10 The dominant hr HPV types in anogenital carcinomas are HPV 16 (range, 40.9-82.2 %) and HPV 18 (44.7 % of adenocarcinomas of the cervix, 2.6-18.1 % at other locations). 11 The human pathogenic papillomaviruses are strictly epitheliotropic. Most HPV infections are transient infections, asymptomatic or subclinical and therefore not recognized. They usually heal in about 4 to 20 months and do not cause neoplasia, 12 whereas in some cases, for example in HIV + patients, HPV infections can increase the incidence of cancer. [13] [14] [15] The overall life expectancy of HIV + patients has increased in the last two decades due to the wide use of antiretroviral therapy (ART). [16] [17] [18] Additionally, anal intraepithelial neoplasia of grade 2 or 3 can be reduced by using quadrivalent HPV vaccines in men who have sex with men (MSM). 19 Nowadays, the incidence of cervical cancer can be reduced by 83 % through specific precautionary vaccination against the HPV types 16,18, 31, 33, and 45. 20 The aim of this study was to compare the HPV infection pattern with histology in immunocompromised and non-immunocompromised patients. Moreover, the histological grading was compared to the molecular analysis to distinguish the different entities. Based on the results, a predictive score was established and evaluated to determine the risk of developing IN in immunocompromised patients. This score is expected to improve clinical assessment.
Materials and methods

Patient population
The patient collective of this retrospective study consists of patients presenting at the Department of Dermatology of the Ludwig-Maximilian-University in Munich, Germany, from February 2010 to August 2015 who were treated according to the guidelines for prevention of anal cancer of the German AIDS Society. The study was independent of gender, age or nationality. All data were collected and processed anonymously.
Ethics committee
The ethics committee of LMU Munich reviewed and approved the ethical safety of the planned fully anonymized retrospective study of the prevalence of HPV types in diagnostic scans and tissue samples of cutaneous neoplasia in immunosuppressed and non-immunosuppressed patients.
Data collection
The data were collected from the electronic patient file. Additionally, for diagnostic purposes stored biopsies were re-analysed for HPV types.
Statistical evaluation
All data were statistically analysed with SPSS (Statistics â Version 23 IBM Inc, Armonk, NY, USA). The corresponding images were generated using GraphPad Prism 5 software (GraphPad Software Inc., La Jolla, CA/USA). Significance testing (significance level a = 0.05) was performed using the Pearson chisquare test and Fisher's exact test. The strength of each effect was determined by Cramer's V test.
Patient group
Out of 150 patients, 29 patients (19.3 %) had to be excluded from this study because of incomplete data sets or insufficient tissue material. The gender distribution of the remaining 121 patients included 14 women (11.6 %) and 107 men (88.4 %).
The mean patient age (years AE SD) was 47.8 AE 14.3 years. The youngest patient was 24 years, the oldest 87 years old.
Tissue samples
Anogenital biopsy tissue samples were taken during clinical routine controls that included biopsy and were stored in the histological archive. For this study, they were retrospectively analysed and tested for HPV.
Samples were collected from February 2010 to August 2015, fixed with 10 % formalin (Merck KGaA, Darmstadt, Germany), paraffin (Merck KGaA) embedded and HE-stained (Merck KGaA, Darmstadt, Germany). Originally, only HIV + patients were considered. However, we did not find enough HIV + patients to test for HPV types. Therefore, we analysed samples from our histological database (ZOC-Database).
One or more tissue samples from each patient were analysed retrospectively. In total, 245 tissue samples were analysed; after the presence of tissue in the paraffin-embedded samples could be confirmed, a total of 210 (85.7 %) tissue samples underwent further histological and molecular genetic analysis.
From 59 patients (48.8 %) one tissue sample, from 39 patients (32.2 %) two tissue samples, from 20 patients (16.5 %) three tissue samples, from two patients (1.7 %) four tissue samples and from one patient (0.8 %) five tissue samples were collected.
Histological evaluation
All 210 tissue samples underwent histopathological examination by a board-certified dermatohistopathologist who assigned them to their diagnostic entities. The DNA chips from Chipron (Berlin/Germany) were developed for the identification and differentiation of clinically relevant human alpha-papillomaviruses, in total 32 different types (6, 11, 16, 18, 31, 33, 35, 39, 42, 44, 45 , 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 67, 68, 70, 72, 73, 81, 82, 83, 84, 90, 91). The kits consist of a primer system as well as HPV-chip arrays. The primer system 'MY09/11' is based on the sequences MY09 and MY11 and generates PCR amplifications of the size of about 450 base pairs. To prove the overall conditions (primer quality, PCR success), an agarose gel electrophoresis preceded the chip analysis. Besides, the additional PCR kit was performed according to the manufacturer's instructions and evaluated with the company's SlideReader and V12 software (Chipron).
Generation of the RICH (Risk of Carcinoma in HIV + patients) score
Based on the histological findings, chip analysis and serological HIV testing, the RICH score was generated and patients tested accordingly. 
Results
Histological grading
Distribution of hr HPV, lr HPV and mixed infections in comparison with histological findings
Tissue samples were subdivided into four HPV status dependent groups: Without HPV, high-risk HPV (hr HPV) only, low-risk HPV (lr HPV) only and mixed infections (hr HPV and lr HPV). These groups were compared with respect to their histological findings ranging from unremarkable, IN 1, IN 2, IN 3, and condylomata acuminata. Of the 32 potentially detectable HPV types, DNA from HPV 35, 51, and 73 was never detected. All other types delivered type-specific results with incidences between approximately 1 % and 50 % (data not shown). No evidence for present HPV DNA could be found in any of the specimens that were histologically unremarkable. In the IN 1 group, the hr HPV type 16 was identified in one sample (6.7 %), while the remaining 14 samples were HPV negative or contained at least one lr HPV type. In the IN 2 group, at least one hr HPV type was identified in three samples (18.9 %). 13 samples were HPV negative or contained at least one lr HPV type. In the IN 3 group, at least one hr HPV type was identified in 56 samples, while 27 samples were HPV negative or contained at least one lr HPV type. This corresponds to a prevalence of hr HPV in 67.5 % of the IN 3 samples. Within the group of condylomata acuminata, four samples out of 88 in total were positive for at least one hr HPV type and 22 samples for at least one hr HPV type in combination with one or more lr HPV types. Hr HPV prevalence was 29.5 % among all condylomata acuminata. (Table 1 )
Comparison of HPV detection using chip versus histological analysis
The detection of the HPV types in IN 3 showed the same sensitivity when the molecular analysis and the histological method were compared. For the HPV types IN 1 and IN 2, the molecular analysis was less sensitive compared with histology ( Fig. 1 ).
Analysis of histological grading and molecular genetic HPV detection
Hr HPV and lr HPV were compared to their histological grading. There was a significant correlation between the presence of hr or lr HPV types and the histology (v 2 (3) = 44.51, P ≤ 0.001 / Fisher's exact test: P ≤ 0.001) ( Table 2) .
Correlation analysis of condylomata acuminata and lr HPV type Scores >4 recommend precise screening every 3 months, including high-resolution anal anoscopy and biopsy (Fig. 2) . Given the case that only cytology/HPV status and HIV status are available, we suggest screening procedures every 3 months if patients receive a score >2.
Testing the efficacy of the RICH score in 121 patients
The data of the 91 fully assigned (with available HIV status) patients were used to assess their RICH score ( Fig. 3 ). Of note, most patients were HIV + and therefore commonly had RICH scores >4, receiving recommendation for precise screening procedures every three months. Moreover, the RICH score could clearly separate patients that have a low risk of disease progression.
Discussion
Human alpha-papillomavirus infections are increasingly related to malignancy of tumours in female and male individuals. 
HIV/HPV co-infection
Immunocompromising diseases like HIV infections encourage HPV infection and strongly increase the risk of developing IN or anogenital carcinoma. 22, 25 In accordance with this correlation, hr HPV types were detected in only 15.4 % of the condylomata acuminata of HIV À patients. In contrast, hr HPV types were present in 47.5 % of HIV + patients with condylomata acuminata. This indicates that HIV may also increase the risk of malignant transformation of condylomata acuminata. 26 Surprisingly, this correlation could not be confirmed in the entity of IN 3 which showed a decrease of hr HPV types in HIV + samples, but an increase in lr HPV types. However, information about the duration of HIV infection as well as the HIV status in 23.8 % of the samples is missing. Another limitation is the heterogeneous group of samples (perianal, anal, penile, vulvar) and small sample numbers in some of the subgroups. Moreover, this study lacks a T-cell count correlating with immune function. Formerly, therapy derived immunosuppression was supposed to have no influence on the infection with HPV. 22 Literature about HPV status under immunosuppression is controversial, and our data clearly indicate a correlation between HIV prevalence and HPV infection.
Chip testing vs. histology
In IN 1 and 2, the molecular analysis was more sensitive in detecting HPV types compared to histological examination. The detection sensitivity in IN 3 was however similar using both methods. We hereby conclude that molecular analysis is more precise in distinguishing HPV types in IN 1 and 2. This might be due to the sensitivity of this PCR based method, being able to detect low amounts of HPV DNA.
Correlation of hr HPV with the oncologic grade (IN 1-3) We observed an increased hr HPV prevalence that correlates positively with a higher oncological grade: In 13.3 % of IN 3 samples, no HPV was detected. We speculate that not enough DNA material was present. Another reason might be that the used chip detected only 32 of over 200 yet discovered HPV types. Based on our data, we speculate that the potentially not detected HPV types may still have oncogenic potential.
Mixed hr HPV infections as a major risk factor
Most hr HPV mixed infections were observed in IN 3, but not in condylomata acuminata. We speculate that mixed infections might increase the risk of malignant transformation. Moreover, we detected a variety of HPV types and mixed infections even in low-graded neoplasias (IN 1 and 2) . We speculate that lowgraded neoplasias with mixed infections are more likely to turn into IN 3. That is why even IN 1 and 2 patients with numerous HPV types should perform regular screening procedures.
Furthermore, it was shown that condylomata acuminata contained many different HPV types. Among these, 29.5 % of the cases showed hr HPV types (HPV 16 = 13.6 %, HPV 18 = 6.8 %, HPV 39 = 5.7 %). This explains why benign tumours like condylomata acuminata have oncogenic potential. Hence, new prevention procedures against HPV infections might be effectively preventive.
Preventing IN 1-3 by early HPV vaccination
The two vaccines Gardasil â (Merck Sharp & Dohme Corp, USA) and Cervarix â (GlaxoSmithKline, UK) revealed high efficacy and cross-protection to other HPV types. 20, 27 Gardasil 9, for instance, targets the HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58. 27 After introducing a public vaccination programme in Australia, a significant decrease of HPV infections was observed. 28, 29 Furthermore, HPV vaccination is now recommended for boys between 9 and 14 (17) years old by the German Standing Committee on Vaccination (STIKO). 30 As IN are the precursor lesions for anogenital carcinomas, 23 we find that screening programmes for the recognition and treatment of HPV infections should be promoted, especially for immunosuppressive patients.
The American STI-guidelines of the centre for disease control recommend a vaccination for men to produce herd immunity. 31 HPV is mainly sexually transmitted and fulfils the criteria for a global pandemic. Often young patients in the sexually active age are affected by HPV infection and therapy is difficult, longwinded and expensive. The vaccination is approved in many countries for girls and boys between the ages of 9 and 17 to prevent anogenital dysplasia. 32 
Introduction of the RICH score
The higher the histopathological grade of anal intraepithelial neoplasia the higher the risk of developing anal cancer, especially in HIV + patients. 33 Additionally, almost all precursor lesions and anal cancers are hr HPV positive, indicating that early screening procedures are beneficial. 23, 34 Anal cancer screening should be performed in all HIV + patients and highrisk patients, which are marked by a history of condylomata acuminata, or IN, or HPV-associated cancer, or persistent hr HPV infection. 35 For example, IN 3 receiving topical treatment should be repeatedly screened with inspection, palpation, swab, cytology, anoscopy and if necessary biopsy. 35 This is also reflected in the RICH score which compared to other screening algorithms (like presented in 35 ) facilitates the analysis and may therefore be suitable for clinical routine. We also included condylomata acuminata in the score since it lacks control and elimination of an HPV infection (similar to IN 1-3) , and it is also associated with an increased prevalence of anal cancer in HIV + patients. 35 Condylomata is caused by lr HPV infection, indicating that even lr HPV types can also be sufficient to develop anal cancer after persistent infection. To improve the outcome of yet infected HPV +/À /HIV +/À patients with anal intraepithelial neoplasia or condylomata acuminata, we generated the RICH score. This screening tool was generated based on our observations and literature and suggests differential examination intervals based on HIV status, molecular genetic results and histological findings, similar to studies performed for anal cancer. 36, 37 Screening procedures should include highresolution anal anoscopy and biopsy. Moreover, patients at low risk could clearly be separated from high-risk patients, while a large proportion was assigned to the area between high and low risk. Especially these patients may be regrouped at their semiannual visits. This study though mainly includes HIV + patients, which automatically result in high RICH scores. We conclude that the RICH score offers an easy tool to assign patients to different risk groups.
However, further studies are required to show the outcome of HIV + and HIV À patients using screening approaches based on recommendations of the RICH score.
